These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25385055)

  • 1. Selumetinib for the treatment of cancer.
    Ciombor KK; Bekaii-Saab T
    Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
    Patel SP; Kim KB
    Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibitors under development for treatment of non-small-cell lung cancer.
    Kim C; Giaccone G
    Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
    Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
    Dry JR; Pavey S; Pratilas CA; Harbron C; Runswick S; Hodgson D; Chresta C; McCormack R; Byrne N; Cockerill M; Graham A; Beran G; Cassidy A; Haggerty C; Brown H; Ellison G; Dering J; Taylor BS; Stark M; Bonazzi V; Ravishankar S; Packer L; Xing F; Solit DB; Finn RS; Rosen N; Hayward NK; French T; Smith PD
    Cancer Res; 2010 Mar; 70(6):2264-73. PubMed ID: 20215513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
    Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
    Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
    Hedayat M; Jafari R; Majidi Zolbanin N
    Clin Exp Med; 2023 Jun; 23(2):229-244. PubMed ID: 35171389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
    Davies BR; Logie A; McKay JS; Martin P; Steele S; Jenkins R; Cockerill M; Cartlidge S; Smith PD
    Mol Cancer Ther; 2007 Aug; 6(8):2209-19. PubMed ID: 17699718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
    Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
    Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
    Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
    Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
    Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS
    Kenney C; Kunst T; Webb S; Christina D; Arrowood C; Steinberg SM; Mettu NB; Kim EJ; Rudloff U
    Invest New Drugs; 2021 Jun; 39(3):821-828. PubMed ID: 33405090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.